Search Bar & Filters
Found 39 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating SYX-5219 in a multi-part, first-in-human Phase 1 study involving healthy volunteers and people with moderate to severe atopic dermatitis AD. The study aims to determine the safety, tolerability, and levels of SYX-5219 in blood and urine when given in different dosing schedules. This includes single ascending doses, multiple ascending doses, and multiple dose administrations in participants with AD. The study has three parts Part 1 involves single ascending doses and a food effect evaluation in healthy volunteers, with doses given once on Day 1 and again after a washout period. Part 2 involves multiple ascending doses given once or twice daily to healthy volunteers over a defined period. Part 3 enrolls participants with AD who receive SYX-5219 or placebo twice daily for up to 42 days. Each part includes randomization and placebo control to compare effects. Participants will undergo safety and exploratory efficacy assessments during and after treatment, including monitoring adverse events up to 10 days after dosing in Part 1, 14 days after the last dose in Part 2, and up to Day 56 in Part 3. Blood and urine samples are collected at multiple timepoints to measure SYX-5219 levels. The study includes follow-up visits to monitor participant health and drug effects for several weeks after treatment ends.
Actively Recruiting
This research aims to evaluate the long-term safety and efficacy of APG777 in adults with moderate-to-severe atopic dermatitis who have already completed treatment in a prior APG777 study. The study is a multicenter, double-blind, phase 2 extension designed for participants who, according to the investigator, could benefit from continued APG777 treatment. The study consists of three periods a Screening Visit coinciding with the last visit of the parent studys Maintenance Period an Extended Treatment Period where participants maintain their APG777 dose from the previous study or receive open-label APG777 if they did not meet certain response criteria and a Post-treatment Follow-up Period. Participants receive APG777 as subcutaneous injections every 12 or 24 weeks, depending on their previous dosing regimen or study arm assignment. During the study, participants will have assessments for safety and efficacy, including monitoring treatment-emergent adverse events for up to 3 years. Researchers will also track improvements in eczema severity, itch symptoms, use of rescue therapy, and serum drug concentrations over an average of 2 years during the Extended Treatment Period. Participation may last up to 3 years, including follow-up to observe long-term outcomes.
Actively Recruiting
Researchers are evaluating BIOxHEAL, a placental-derived biologic, for treating nonhealing diabetic foot ulcers in adults with type 1 or type 2 diabetes. This phase 3, open-label, randomized controlled trial aims to determine whether BIOxHEAL combined with standard wound care increases the rate of complete ulcer closure by Week 12 compared to standard care alone. The study includes an initial non-randomized sentinel group to assess early safety before proceeding to the randomized phase. In the initial sentinel cohort, participants receive BIOxHEAL plus standard of care once weekly for up to 12 weeks or until the ulcer fully closes. After safety review, 243 participants are randomized 21 to receive either BIOxHEAL with standard care or standard care alone, with treatments administered weekly for up to 12 weeks or until complete ulcer closure. Closure is confirmed about two weeks after treatment ends. Participants are followed for an additional three months to monitor outcomes. Participants will attend weekly visits for treatment and monitoring during the study. Assessments include ulcer measurements and confirmation of complete wound closure. Researchers will track wound healing rates, safety events, quality of life changes, and amputation occurrences for up to six months. The primary outcome is the proportion of ulcers fully closed by Week 12. This study is sponsored by Applied Biologics, LLC, and participation may last several months including treatment and follow-up.
Actively Recruiting
Researchers are evaluating the drug TRIV-573 for treating moderate to severe atopic dermatitis in adults. This phase 2, randomized, double-blind, placebo-controlled study aims to assess both the effectiveness and safety of multiple doses of TRIV-573 compared to placebo. The study is sponsored by Triveni Bio and focuses on improving symptoms of atopic dermatitis over 16 weeks. Participants will be randomly assigned to receive five subcutaneous injections of either TRIV-573 or a placebo. The study includes a screening period lasting up to 30 days before treatment begins. The total duration for each participant is up to 40 weeks, covering treatment and follow-up phases. During the study, participants will undergo regular assessments to monitor their skin condition and safety. Researchers will measure the percentage of participants showing improvement in atopic dermatitis from baseline through week 16. Safety will be evaluated by tracking adverse events and analyzing blood samples for drug levels and antibody formation through week 36. Participants will attend scheduled visits for these evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are evaluating remibrutinib in adult participants with severe chronic pruritus of unknown origin CPUO, a condition causing persistent severe itching without a known cause. This phase 3, global, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, and tolerability of remibrutinib for this condition. Participants will undergo up to 60 weeks of study divided into four periods. After a screening period of up to 4 weeks, participants enter a 24-week double-blind phase receiving either remibrutinib or placebo. Then, a 28-week open-label phase follows, where all participants receive remibrutinib. Lastly, there is a 4-week treatment-free safety follow-up period. Throughout the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity. Researchers will monitor sleep disturbance related to itching, record adverse events, and evaluate treatment tolerability. The entire participation can last up to 60 weeks, including treatment and follow-up phases.
Actively Recruiting
Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.
Actively Recruiting
Researchers are studying the long-term safety, tolerability, and effectiveness of remibrutinib in adults with moderate to severe hidradenitis suppurativa who have finished previous Phase 3 studies. This global Phase 3 extension trial continues to evaluate remibrutinibs impact over several years, fulfilling commitments to provide continued access to the treatment. Participants will continue their assigned blinded dose of remibrutinib from the prior studies until final analysis or dose adjustment. Afterward, treatment shifts to an open-label phase, lasting until commercial availability, reimbursement, alternative access, or four years of extension treatment are completed. Those ending treatment early or not transitioning to commercial remibrutinib enter a four-week safety follow-up without treatment. Throughout the study, participants undergo regular monitoring for adverse events and treatment responses using scales such as the International Hidradenitis Suppurativa Severity Score System and clinical response measures up to week 276. The study emphasizes safety and long-term effects, with participation lasting up to several years including follow-up, ensuring comprehensive data collection on remibrutinibs use in this condition.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Healthy Volunteer
Researchers are studying the Caris Biorepository, a project designed to collect and store high-quality biological specimens and related clinical data to support research aimed at advancing precision medicine and improving patient care. This observational study focuses on gathering samples and information from various sources, including healthy individuals and cancer patients, to help understand disease treatments and clinical outcomes. The biorepository includes samples from different donor groups, such as those with no disease, treatment-nave patients with new solid tumors, individuals at higher risk for cancer, patients with advanced cancer, and those with a history of cancer but no active disease. The project aims to maintain molecular integrity and clinical relevance of these specimens while providing access to researchers and collaborators for drug development, clinical trials, and healthcare policy enhancements. Participants provide informed consent and contribute biological samples and clinical data that are securely stored and shared for research purposes. The study measures include ensuring specimen quality and relevance over 35 years and facilitating specimen release for testing. Laboratory testing will be conducted throughout the study duration. The project supports long-term research collaboration and aims to impact patient outcomes and treatment practices over time.
1-10 of 39
1